KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Operations (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Cash from Operations data on record, last reported at 48761000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 10.99% year-over-year to 48761000.0; the TTM value through Sep 2025 reached 189739000.0, down 7.46%, while the annual FY2024 figure was 175709000.0, 8.77% up from the prior year.
  • Cash from Operations reached 48761000.0 in Q3 2025 per NKTR's latest filing, down from 45738000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 37702000.0 in Q2 2024 and bottomed at 151538000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 64659684.21, with a median of 51523000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: plummeted 92.0% in 2021, then soared 61.92% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 151538000.0 in 2021, then surged by 61.92% to 57703000.0 in 2022, then grew by 18.47% to 47047000.0 in 2023, then increased by 1.83% to 46187000.0 in 2024, then decreased by 5.57% to 48761000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 48761000.0 in Q3 2025, 45738000.0 in Q2 2025, and 49053000.0 in Q1 2025.